Revelation Biosciences, Inc. (NASDAQ:REVB) | WebDisclosure

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Headlines Articles Press releases Revelation Biosciences, Inc.

Home
Companies
Revelation Biosciences, Inc.

PRESS RELEASE

published on 09/10/2025 at 13:20, 2 months 24 days ago

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Gemini showed significant reduction in inflammation at the cellular level in CKD patients according to Phase 1b study results. Groundbreaking potential in inflammatory disease treatment

Inflammation CKD Gemini Phase 1b Study Cellular Level
BRIEF

published on 09/09/2025 at 23:00, 2 months 25 days ago

Revelation Biosciences s'apprête à discuter des données de la phase 1b lors d'une prochaine conférence téléphonique

Webcast Essais Cliniques Inflammation Revelation Biosciences Étude De Phase 1b
BRIEF

published on 09/09/2025 at 23:00, 2 months 25 days ago

Revelation Biosciences Set to Discuss Phase 1b Data in Upcoming Conference Call

Clinical Trials Webcast Inflammation Revelation Biosciences Phase 1b Study
PRESS RELEASE

published on 09/09/2025 at 22:55, 2 months 25 days ago

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences, Inc. (NASDAQ:REVB) reminds of webcast on Sept 10, 8:30 am ET. Focus on inflammation. Seeking to rebalance inflammation for various medical conditions

Webcast Clinical-stage Inflammation Gemini Revelation Biosciences
BRIEF

published on 09/09/2025 at 14:05, 2 months 25 days ago

Revelation Biosciences' PRIME Study Shows Promising Results for Gemini in Inflammatory Diseases

Clinical Results Gemini Revelation Biosciences PRIME Study Inflammation Treatment
BRIEF

published on 09/09/2025 at 14:05, 2 months 25 days ago

L'étude PRIME de Revelation Biosciences montre des résultats prometteurs pour Gemini dans les maladies inflammatoires

Résultats Cliniques Revelation Biosciences Gémeaux Étude PRIME Traitement De L'inflammation
PRESS RELEASE

published on 09/09/2025 at 14:00, 2 months 25 days ago

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences reports positive safety and activity data for Gemini in phase 1b PRIME study for CKD patients, showing reduction in inflammatory activity and cellular response normalization

Clinical Study Gemini Revelation Biosciences CKD Patients Inflammatory Response

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 27 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 37 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 13 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:14, 13 hours 13 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 28 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 43 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE